Boehringer Ingelheim reported positive Phase 3 results from the SYNCHRONIZE-1 trial of survodutide (BI 456906), a dual-action drug that activates GLP-1 and glucagon receptors. The international trial enrolled 725 adults with overweight or obesity (excluding those with type 2 diabetes) and evaluated weekly injections over 76 weeks.
Results
– Average weight loss with survodutide was 16.6% (about 39.2 pounds), versus 3.2% for placebo.
– Up to 85.1% of people on survodutide achieved at least a 5% reduction in body weight, compared with 38.8% on placebo.
– Participants received weekly doses of 3.6 mg or 6.0 mg.
– Waist circumference decreased significantly, suggesting reductions in visceral fat and cardiometabolic risk.
– Most weight loss was composed of fat rather than lean muscle.
– Common GLP-1–type gastrointestinal side effects (nausea, vomiting) were mostly mild to moderate, tended to occur during dose escalation, and were transient. No new safety signals were reported in the announcement.
How survodutide differs from tirzepatide (Mounjaro/Zepbound)
– Survodutide combines GLP-1 receptor agonism with glucagon receptor activity, a different receptor combination than tirzepatide’s dual GIP/GLP-1 action.
– The added glucagon activity may influence liver metabolism, potentially reducing liver fat and improving markers of inflammation or fibrosis—raising interest in obesity-related liver disease treatment.
Expert perspectives
– Hector Perez, MD, a bariatric surgeon and advisor, called the weight-loss figures impressive but cautioned it’s too early to declare survodutide a “game-changer.” He emphasized waiting for full data and noted that real-world effectiveness depends on tolerability and whether patients can stay on the drug.
– Perez highlighted potential value for fatty liver disease because the glucagon component might help reduce liver fat and inflammation, improving metabolic drivers of liver damage.
– Kristin Kuminski, RDN, said the results are “significant” and comparable to tirzepatide but advised patients to discuss with clinicians how a new drug might compare on side effects and in people with coexisting conditions.
Practical considerations
– Survodutide is not yet approved; conversations with clinicians now are about pipeline developments and possible trial participation.
– Questions to discuss with a doctor include candidacy for bariatric surgery, realistic expectations for weight loss, strategies to protect muscle mass, expected side effects, what happens after stopping the medication, and insurance coverage.
– Experts stress choosing treatments that fit a patient’s body, habits, finances, and ability to sustain long-term therapy rather than being swayed only by headline efficacy numbers.
Bottom line
Survodutide’s Phase 3 results show substantial and sustained weight loss and metabolic improvements in people without diabetes, with a safety profile similar to other GLP-1–based therapies in this announcement. Its glucagon activity raises particular interest for potential liver benefits, but full trial data and regulatory review are needed before treatment implications versus existing options like tirzepatide/Zepbound can be fully assessed.
